The phrase "arise in developing countries" is correct and usable in written English.
It can be used when discussing issues, challenges, or phenomena that occur specifically in developing nations.
Example: "Many health crises tend to arise in developing countries due to limited access to medical resources."
Alternatives: "emerge in developing nations" or "occur in developing countries."
Oral cancer is the sixth most common cancer reported globally with an annual incidence of over 300,000 cases, of which 62% arise in developing countries [ 1].
Current estimates from the American Cancer Society and from the International Union against Cancer indicate that 12 million cases of cancer were diagnosed last year, accounting for 8.2 million deaths in 2012 worldwide; these numbers are expected to double by 2030, of which 62% arise in developing countries (27 million cases with 17 million deaths) [ 1– 4].
The availability of water and the ability to access are the key questions arising in developing countries including Jordan, which is the fourth poorest country in the world regarding water resources.
This divide in research funding is mirrored by concerns regarding a divide in the proportion of publications arising from medical research in developing countries.
If true, this may be partly due to higher HIV prevalence in urban areas, 62 84 and partly due to loss of the 'urban advantage' in maternal health now arising in urban populations in developing countries, 85 although a lack of access to skilled delivery in rural areas would be expected to counterbalance the lower HIV-related maternal mortality.
EME non-financial corporate debt has been on the rise Back in 2013, I called attention to new features of international long-term private debt finance in developing countries that arose since the global financial crisis.
As the phenomenon of corporate social responsibility (CSR) establishes itself more globally, the question arises as to the nature of CSR in developing countries.
And nonprofit drug organizations, backed by contributions from philanthropists, have arisen to try to develop drugs for diseases in developing countries, like malaria and tuberculosis, which tend to be neglected by pharmaceutical companies.
As research has become increasingly globalised, the ethical issues arising from international collaborative research where samples are collected in developing countries and exported to developed countries for analysis are particularly complex.
She also considered the relationship between IP protection and public health in developing countries, using specific cases that have arisen under the World Trade Organization's Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS).
Access to antiretroviral therapy (ART) is improving in developing countries which experience the greatest disease burden arising from HIV infection.
